Literature DB >> 20333554

Capturing and characterizing immune cells from breast tumor microenvironment: an innovative surgical approach.

Mohamed El-Shinawi1, Sayed F Abdelwahab, Maha Sobhy, Mohamed A Nouh, Bonnie F Sloane, Mona Mostafa Mohamed.   

Abstract

BACKGROUND: In breast cancer patients, venous drainage of the breast may contain cells of immunological importance, tumor cells undergoing dissemination, and other biological factors derived from the tumor microenvironment. Collecting axillary venous blood during modified radical mastectomy and thus before dilution in the circulation may allow us to define biological properties of the tumor microenvironment. Aims were to (1) develop a surgical approach to collect blood from the breast tumor microenvironment through tributaries of the axillary vein and (2) characterize and compare immune cells collected from the axillary vein with those in peripheral blood of breast cancer patients.
MATERIALS AND METHODS: We enrolled 17 women aged 30-50 years and diagnosed with breast cancer by mammography, ultrasound, and biopsy (stages II-III). All patients were, preoperatively, treatment-naive. During routine surgical dissection, blood was collected in heparin tubes, 10 mL from tributaries of the axillary vein and 10 mL from peripheral blood. Mononuclear cells were separated, and percentages of different leukocyte populations were determined by flow cytometry.
RESULTS: We detected a significant increase in the percentage of total T lymphocytes and T helper cells collected from axillary tributaries, but not in the percentages of cytotoxic T cells, monocytes, natural killer, or B cells compared with peripheral blood.
CONCLUSIONS: The present study validated using an intraoperative surgical approach to collect leukocytes drained from the tumor microenvironment through axillary tributaries. Our results showed an increase in the infiltration of total T-lymphocytes and T helper cells in the tumor microenvironment, suggesting that they may contribute to tumor pathogenesis.

Entities:  

Mesh:

Year:  2010        PMID: 20333554      PMCID: PMC3402355          DOI: 10.1245/s10434-010-1029-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  32 in total

1.  Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems.

Authors:  C Genestie; B Zafrani; B Asselain; A Fourquet; S Rozan; P Validire; A Vincent-Salomon; X Sastre-Garau
Journal:  Anticancer Res       Date:  1998 Jan-Feb       Impact factor: 2.480

2.  High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer.

Authors:  Sytse J Piersma; Ekaterina S Jordanova; Mariëtte I E van Poelgeest; Kitty M C Kwappenberg; Jeanette M van der Hulst; Jan W Drijfhout; Cornelis J M Melief; Gemma G Kenter; Gert Jan Fleuren; Rienk Offringa; Sjoerd H van der Burg
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

Review 3.  Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.

Authors:  K L Knutson; M L Disis
Journal:  Cancer Immunol Immunother       Date:  2005-01-27       Impact factor: 6.968

4.  Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in reactive and neoplastic lymphoid cells.

Authors:  M Stetler-Stevenson; A Mansoor; M Lim; P Fukushima; J Kehrl; G Marti; K Ptaszynski; J Wang; W G Stetler-Stevenson
Journal:  Blood       Date:  1997-03-01       Impact factor: 22.113

Review 5.  Distinct role of macrophages in different tumor microenvironments.

Authors:  Claire E Lewis; Jeffrey W Pollard
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

6.  Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Authors:  Jérôme Galon; Anne Costes; Fatima Sanchez-Cabo; Amos Kirilovsky; Bernhard Mlecnik; Christine Lagorce-Pagès; Marie Tosolini; Matthieu Camus; Anne Berger; Philippe Wind; Franck Zinzindohoué; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

7.  Lymphocyte infiltrates as a prognostic variable in female breast cancer.

Authors:  S Aaltomaa; P Lipponen; M Eskelinen; V M Kosma; S Marin; E Alhava; K Syrjänen
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

8.  Does the presence of circulating tumor cells in the venous drainage of curative colorectal cancer resections determine prognosis? A meta-analysis.

Authors:  Hidetoshi Katsuno; Emmanouil Zacharakis; Omer Aziz; Christopher Rao; Samer Deeba; Paraskeva Paraskeva; Paul Ziprin; Thanos Athanasiou; Ara Darzi
Journal:  Ann Surg Oncol       Date:  2008-09-12       Impact factor: 5.344

9.  Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma.

Authors:  R D Leek; C E Lewis; R Whitehouse; M Greenall; J Clarke; A L Harris
Journal:  Cancer Res       Date:  1996-10-15       Impact factor: 12.701

10.  The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators.

Authors:  Stavros N Georgiannos; Andrew Renaut; Anthony W Goode; Michael Sheaff
Journal:  Surgery       Date:  2003-11       Impact factor: 3.982

View more
  7 in total

1.  Secretome of tumor-associated leukocytes augment epithelial-mesenchymal transition in positive lymph node breast cancer patients via activation of EGFR/Tyr845 and NF-κB/p65 signaling pathway.

Authors:  Eslam A Elghonaimy; Sherif A Ibrahim; Amal Youns; Zeinab Hussein; Mohamed Akram Nouh; Tahani El-Mamlouk; Mohamed El-Shinawi; Mona Mostafa Mohamed
Journal:  Tumour Biol       Date:  2016-06-22

2.  Inflammatory Breast Cancer Promotes Development of M2 Tumor-Associated Macrophages and Cancer Mesenchymal Cells through a Complex Chemokine Network.

Authors:  Amanda Valeta-Magara; Abhilash Gadi; Viviana Volta; Beth Walters; Rezina Arju; Shah Giashuddin; Hua Zhong; Robert J Schneider
Journal:  Cancer Res       Date:  2019-05-01       Impact factor: 12.701

3.  Inflammatory Breast Cancer: The Secretome of HCMV+ Tumor-Associated Macrophages Enhances Proliferation, Invasion, Colony Formation, and Expression of Cancer Stem Cell Markers.

Authors:  Hossam Taha Mohamed; Aya Ali El-Sharkawy; Mohamed El-Shinawi; Robert J Schneider; Mona Mostafa Mohamed
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

4.  Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties.

Authors:  Mona M Mohamed; Eslam A El-Ghonaimy; Mohamed A Nouh; Robert J Schneider; Bonnie F Sloane; Mohamed El-Shinawi
Journal:  Int J Biochem Cell Biol       Date:  2013-11-26       Impact factor: 5.085

5.  Prognostic impact of perioperative lymphocyte-monocyte ratio in patients with bladder cancer undergoing radical cystectomy.

Authors:  Takashi Yoshida; Hidefumi Kinoshita; Kenji Yoshida; Takao Mishima; Masaaki Yanishi; Hidekazu Inui; Yoshihiro Komai; Motohiko Sugi; Takaaki Inoue; Takashi Murota; Katsuya Fukui; Jiro Harada; Gen Kawa; Tadashi Matsuda
Journal:  Tumour Biol       Date:  2016-01-27

6.  The immunomodulatory role of tumor Syndecan-1 (CD138) on ex vivo tumor microenvironmental CD4+ T cell polarization in inflammatory and non-inflammatory breast cancer patients.

Authors:  Moshira Ezzat Saleh; Ramy Gadalla; Hebatallah Hassan; Ahmed Afifi; Martin Götte; Mohamed El-Shinawi; Mona Mostafa Mohamed; Sherif Abdelaziz Ibrahim
Journal:  PLoS One       Date:  2019-05-30       Impact factor: 3.240

7.  Leptin is overexpressed in the tumor microenvironment of obese patients with estrogen receptor positive breast cancer.

Authors:  Mohamed Hosney; Salwa Sabet; Mohamed El-Shinawi; Khadiga M Gaafar; Mona M Mohamed
Journal:  Exp Ther Med       Date:  2017-03-30       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.